EBetween June 21 and 27, 2024, the National Agency for the Safety of Medicines and Health Products (ANSM) reported new disruptions or updated the availability data of several specialties marketed in France [1]distributed exclusively to the hospital.
ELDISINE: persistent unavailability
ELDISINE 5 mg powder for solution for injection (vindesine sulfate)
Availability status according to ANSM
Linezolid 2 mg/mL injection specialties: indefinite availability
All laboratories: ZYVOXID 2 mg/mL solution for infusion and its generics ARROW, HIKMA, KABI, PANPHARMA (linezolid)
Availability status according to ANSM
SIMULECT: dosage tension at 20 mg
SIMULECT 20 mg powder and solvent for solution for injection or infusion (basiliximab)
Availability status according to ANSM
- Supply tension, due to production problem (global situation)
- Quantitative quota
- Normal availability mid-August 2024
Additional laboratory information
Letter from Novartis Pharma intended for healthcare professionals (June 21, 2024): strict quantitative quota with reduction in the quantities allocated per healthcare establishment.
SIMULECT 10 mg is not currently impacted by this tension; the laboratory has sufficient stock of this presentation to cover the needs of children and adolescents (1-17 years) weighing less than 35 kg.
TOMUDEX: resumption of supply, but persistence of tensions
TOMUDEX 2 mg poudre pour solution pour perfusion (raltitrexed)
Availability status according to ANSM
Normal availability confirmed
The ANSM has confirmed the normal availability of the following hospital specialties:
